Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The past 12 months have brought numerous exciting advances involving AI and related emerging technologies. Let us not fail to take a short last look at some of the more spectacular flops.
Some investment analysts are predicting a more permissive M&A market, deregulation as a catalyst for growth and fiscal policies that stimulate economic activity. And they see AI as a catalyst in the shift.
After Luigi Mangione, the man accused of killing UnitedHealthcare CEO Brian Thompson, was extradited to New York, federal prosecutors unsealed a new set of murder charges.